Table 3.
Relative vaccine effectiveness of the fourth dose against all-cause mortality in residents of long-term care facilities by number of days after the fourth dose, and according to sex, age, and time passed since vaccination.
| Fourth-dose group |
Third-dose group |
Relative vaccine effectiveness (95% CI) |
||||
|---|---|---|---|---|---|---|
| Deaths | Deaths/100,000 person-days | Deaths | Deaths/100,000 person-days | Adjusted for age and baseline date | Fully adjusted* | |
| 7-60 days, total cohort (N = 21,623) | 573 | 79·8 | 292 | 105·2 | 37 (27-45) | 39 (29-48) |
| Men (N = 6996) | 206 | 89·1 | 97 | 104·2 | 30 (11-45) | 31 (12-46) |
| Women (N = 14,627) | 367 | 75·4 | 195 | 105·7 | 40 (28-50) | 43 (31-53) |
| Age >85 years (N = 12,030) | 389 | 97·0 | 193 | 135·1 | 38 (26-48) | 39 (27-49) |
| Age ≤85 years (N = 9593) | 184 | 58·1 | 99 | 73·5 | 34 (16-49) | 39 (21-52) |
| >4 months since vaccination in the third-dose group (N = 16,809) | 470 | 82·2 | 223 | 122·0 | 45 (35-53) | 46 (36-55) |
| ≤4 months since vaccination dose in the third-dose group (N = 4814) | 107 | 70·6 | 69 | 72·8 | 15 (-16-38) | 20 (-10-43) |
| >4 months since vaccination in the fourth-dose group (N = 20,927) | 549 | 79·0 | 287 | 106·9 | 38 (29-47) | 41 (31-49) |
| 61-126 days, total remaining cohort (N = 13,853) | 214 | 22·0 | 45 | 25·5 | 30 (3-49) | 27 (-2-48) |
CI=confidence interval.
⁎
Adjusted for age, baseline date, sex, born in Sweden, score on Modified Norton Scale, and score on Mini Nutritional Assessment Short-Form Scale.